Subscribe To
KMPH / KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KMPH News
By Seeking Alpha
February 3, 2023
KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating
We initiated KemPharm with a Sell rating in March 2021; since then, the stock has declined >40%, and now the stock is trading at an attractive enterpr more_horizontal
By Seeking Alpha
November 9, 2022
KemPharm, Inc. (KMPH) Q3 2022 Earnings Call Transcript
KemPharm, Inc. (NASDAQ:KMPH ) Q3 2022 Results Conference Call November 9, 2022 5:00 PM ET Company Participants Nichol Ochsner - Vice President of Inve more_horizontal
By Seeking Alpha
May 12, 2022
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2022 Results - Earnings Call Transcript
KemPharm, Inc. (NASDAQ:KMPH ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Travis Mickle - Co-Founder, President, CEO more_horizontal
By Seeking Alpha
March 30, 2022
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q4 2021 Results - Earnings Call Transcript
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Benzinga
January 20, 2022
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id more_horizontal
By Benzinga
January 20, 2022
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id more_horizontal
By Benzinga
January 20, 2022
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id more_horizontal